Nxera Pharma Management
Management criteria checks 2/4
Nxera Pharma's CEO is Chris Cargill, appointed in Mar 2022, has a tenure of 2.42 years. directly owns 0.046% of the company’s shares, worth ¥69.41M. The average tenure of the management team and the board of directors is 2.4 years and 5.4 years respectively.
Key information
Chris Cargill
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | 2.4yrs |
CEO ownership | 0.05% |
Management average tenure | 2.4yrs |
Board average tenure | 5.4yrs |
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -JP¥10b |
Mar 31 2024 | n/a | n/a | -JP¥9b |
Dec 31 2023 | n/a | n/a | -JP¥7b |
Sep 30 2023 | n/a | n/a | -JP¥3b |
Jun 30 2023 | n/a | n/a | JP¥2b |
Mar 31 2023 | n/a | n/a | JP¥1b |
Dec 31 2022 | JP¥292m | JP¥88m | JP¥382m |
Sep 30 2022 | n/a | n/a | -JP¥383m |
Jun 30 2022 | n/a | n/a | -JP¥224m |
Mar 31 2022 | n/a | n/a | JP¥100m |
Dec 31 2021 | JP¥231m | JP¥65m | JP¥1b |
Sep 30 2021 | n/a | n/a | JP¥1b |
Jun 30 2021 | n/a | n/a | JP¥1b |
Mar 31 2021 | n/a | n/a | JP¥1b |
Dec 31 2020 | JP¥157m | JP¥53m | JP¥1b |
Sep 30 2020 | n/a | n/a | -JP¥2b |
Jun 30 2020 | n/a | n/a | -JP¥1b |
Mar 31 2020 | n/a | n/a | -JP¥332m |
Dec 31 2019 | JP¥101m | JP¥40m | JP¥1b |
Compensation vs Market: Insufficient data to establish whether Chris's total compensation is reasonable compared to companies of similar size in the JP market.
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
CEO
Chris Cargill (40 yo)
2.4yrs
Tenure
JP¥292,000,000
Compensation
Mr. Christopher Cargill, also known as Chris, serves as Representative Executive Officer, President, Chief Executive Officer and Director at Nxera Pharma Co., Ltd. (formerly known as Sosei Group Corporatio...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Founder & Chairman of the Board | 19.2yrs | JP¥332.00m | 0.66% ¥ 989.5m | |
Representative Executive Officer | 2.4yrs | JP¥292.00m | 0.046% ¥ 69.4m | |
Executive Officer | 2.4yrs | no data | 0.0016% ¥ 2.3m | |
Executive VP & COO | less than a year | no data | no data | |
Executive Officer | 2.4yrs | no data | 0.0077% ¥ 11.5m | |
Executive Officer | 6.6yrs | no data | 0.0093% ¥ 13.9m | |
VP of Investor Relations & Head of Regulatory Disclosures | no data | no data | no data | |
Associate Director & Head of Biophysics | no data | no data | no data | |
Executive Officer | 1.4yrs | no data | 0.0063% ¥ 9.5m | |
Exe. Off. | 1.1yrs | no data | no data | |
Head of Business Development for Japan and the APAC region | less than a year | no data | no data | |
Hd. of Drug Disc. & UK R&D | 2.4yrs | no data | 0.0031% ¥ 4.6m |
2.4yrs
Average Tenure
51yo
Average Age
Experienced Management: 4565's management team is considered experienced (2.4 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Founder & Chairman of the Board | 19.2yrs | JP¥332.00m | 0.66% ¥ 989.5m | |
Representative Executive Officer | 2.4yrs | JP¥292.00m | 0.046% ¥ 69.4m | |
Member of Scientific Advisory Board | less than a year | JP¥134.00m | no data | |
Independent External Director | 4.4yrs | no data | 0.016% ¥ 23.8m | |
Independent External Director | 13.2yrs | no data | 0.057% ¥ 85.4m | |
External Independent Director | 5.4yrs | no data | 0.038% ¥ 56.9m | |
Independent External Director | 6.2yrs | no data | 0.040% ¥ 59.3m | |
Independent External Director | 6.2yrs | no data | 0.0073% ¥ 10.9m | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
External Independent Director | 2.4yrs | no data | 0.013% ¥ 18.8m |
5.4yrs
Average Tenure
66yo
Average Age
Experienced Board: 4565's board of directors are considered experienced (5.4 years average tenure).